The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Wales reached their first ever semi-final of a major tournament with a magnificent 3-1 victory over Belgium in Lille.
There'll be clear spells overnight which means temperatures will fall. Setting us up for a dry start to the weekend, but it won't last!
Watch the men who have been making history by taking Wales to the quarter-finals of the European Championships.